Zambon
As of the edition of 20 October 2026, Zambon runs 5 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Levodopa | none listed | 4 |
| Carbidopa anhydrous | none listed | 2 |
| Fosfomycin | none listed | 0 |
| Safinamide | Ends 2028 (patent) | 1 |
A route B row is one company at one target.
Where its trials are
- Immune system: 3 trials led
- Lungs and airways: 3 trials led